New Sjögren's drug shows promise in small study
NCT ID NCT05124925
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a drug called ianalumab in 21 adults with Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The goal was to understand how the drug works in the salivary glands and check its safety. Participants received injections of ianalumab and had biopsies to measure changes in immune cells. The results will help researchers decide whether to test the drug in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ianalumab (a biologic drug given as an injection)
What this could lead to
If successful, this study could help explain how ianalumab works in Sjögren's syndrome and support development of a new treatment option for patients.
What could go wrong
This is a small, early-phase study with only 21 participants and no placebo group. Results may not apply to all patients, and the drug may cause side effects or fail to show clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Brest, 29200, France